Clinical Trial Update: Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating sipuleucel-T–based autologous cellular immunotherapy for advanced prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• sipuleucel-T (sipuleucel-T)

Snippet

Sponsor: University of Oklahoma | Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 1 | Status: RECRUITING